Prime Medicine initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Prime Medicine (PRME) with an Outperform rating and $6 price target Prime is developing “one-and-done” gene editing therapies centered around indications with significant unmet need, including Wilson’s disease, alpha-1 antitrypsin deficiency, and cystic fibrosis, the analyst tells investors in a research note. The firm is encouraged by the opportunities Prime is targeting in Wilson’s disease and alpha-1 antitrypsin deficiency.